| Cash Flow | 2025-09-30 |
|---|---|
| Net income (loss) | 30,114 |
| Stock-based compensation | 63,366 |
| Depreciation and amortization | 23,928 |
| Accretion of note premiums/discounts | 5,789 |
| Non-cash interest expense on liability related to the sale of future royalties | 26,036 |
| Non-cash interest expense on credit facility | 63,325 |
| Non-cash gain on treasury stock received | 3,193 |
| Realized loss on investments | 0 |
| Accounts receivable | 56,967 |
| Prepaid expenses and other current assets | 9,939 |
| Accounts payable | 6,286 |
| Accrued expenses | 41,497 |
| Deferred revenue | 2,399 |
| Operating lease, net | -4,605 |
| Other | -3,094 |
| Net cash provided by (used in) operating activities | 179,552 |
| Purchases of property, plant and equipment | 22,666 |
| Purchases of investments | 796,258 |
| Proceeds from sales and maturities of investments | 689,630 |
| Net cash used in investing activities | -129,294 |
| Proceeds from the exercises of stock options | 3,983 |
| Proceeds from the sale of future royalties | 0 |
| Proceeds from the issuance of warrants | 25,000 |
| Payment of debt issuance costs | 5,000 |
| Proceeds from the issuance of common stock, net of offering costs | 241,388 |
| Proceeds from credit facility | 0 |
| Repayments of credit facility | 201,625 |
| Proceeds from visirna credit agreement | 10,260 |
| Net cash provided by financing activities | 74,006 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 124,264 |
| Effect of exchange rate changes on cash | -401 |
| Cash and cash equivalents at beginning of period | 102,685 |
| Cash and cash equivalents at end of period | 226,548 |
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)